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Quality by design (QbD) is a systematic process to build quality into a product from the inception 
to final output. QbD requires a thorough understanding of a product and its process of 
manufacture, necessitating an investment in time and resources upfront in the discovery and 
development of a product. For QbD, the product and process knowledge base must include an 
understanding of variability in raw materials, the relationship between a process and product's 
critical quality attributes (CQAs), and the association between CQAs and a product's clinical 
properties. Here, a QbD approach to method development and validation is presented on 
nateglinide (NTG), an antidiabetic drug. To facilitate studies investigating the determination of 
NTG in bulk drug and its pharmaceutical formulations, we developed and validated a rapid ultra 
performance liquid  chromatography  (UPLC) method for determination of NTG. The validated 
limit of quantitation (LOQ) of 0.06 µg mL-1 and limit of detection (LOD) of 0.02 µg mL-1 are low 
enough to allow determination of low concentrations of the drug. NTG showed no degradation at 
different stress conditions. The relative standard deviation (RSD) percentage for robustness and 
ruggedness were observed within the range of 0.1 and 1.74. The calibration was linear in the range 
of 0.06–250 µg mL-1. The proposed method was compared with a pharmacopoeial reference method 
and found to give equivalent result. The proposed method can be used for routine analysis in 
quality control laboratories for its bulk and formulated product and this is the first reported UPLC 
method for the assay determination of NTG. 
 





The aim of pharmaceutical development is to design a quality product and its 
manufacturing process to consistently deliver the intended performance of the product. 
The information and knowledge gained from pharmaceutical development studies and 
manufacturing experience provide scientific understanding to support the establishment 
of the design space, specifications and manufacturing controls. Information from 
pharmaceutical development studies can be a basis for quality risk management. It is 
important to recognise that quality of the pathway for the method development cannot be 
tested in a product; i.e., quality should be built-in by design. Changes in formulation and 
manufacturing processes during development and lifecycle management should be 
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looked upon as opportunities to gain additional knowledge and further support 
establishment of the design space. Similarly, inclusion of relevant knowledge gained from 
experiments giving unexpected results can also be useful. Design space is proposed by the 
applicant and is subjected to regulatory assessment and approval. Quality by design 
(QbD) [Frederick and Alireza 2010; Center for Drug Evaluation and Research 1994; 
Snyder, Kirkland and Glajchl 1988] is a concept which was first described by Juran (1992). 
QbD deals with getting to market reliably and knowing enough about the limitations and 
risks associated with formulation and production methods in order to establish 
appropriate mitigation and contingency plans. QbD principles have been used to advance 
product and process quality in every industry, and particularly the automotive industry, 
they have most recently been adopted by the US Food and Drug Administration (FDA) 
[International Conference on Harmonisation (ICH) 2006, 2005; USFDA 2004) as a vehicle 
for how the drugs are discovered, developed, and commercially manufactured. Since first 
initiated by the FDA in its "Pharmaceutical cGMPs for the Twenty First Century", QbD has 
become an important concept for the pharmaceutical industry that is further defined in 
the ICH guidance (ICH 1994) on pharmaceutical development as "a systematic approach 
to development that begins with predefined objectives and emphasises product and 
process understanding and process control, based on sound science and quality risk 
management". The scientific understanding gained during the method development 
process can be used to devise method control elements and to manage the risks identified. 
Ultra performance liquid chromatography (UPLC), particularly, is the most popular and 
advanced analytical technique in the pharmaceutical industry. The quality of UPLC 
methods has become increasingly important in a QbD environment. For the purpose of 
QbD for UPLC methods, robustness and ruggedness should be verified early in the 
method development stage to ensure method performance over the lifetime of the 
product.  
Nateglinide (NTG) [3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino] 
propanoic acid] is an oral antihyperglycemic (Drugs.com 2012) agent used for the 
treatment of non-insulin-dependent diabetes mellitus (NIDDM) (Figs. 1 and 2). It belongs 
to the meglitinide class of short-acting insulin secretagogues, which act by binding to β 
cells of the pancreas to stimulate insulin release. NTG is an amino acid derivative that 






Fig. 1: Structure of NTG.  
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Fig. 2: UV absorption spectra of NTG. 
 
NTG is included in the official drafts of United States Pharmacopoeia (United 
States Pharmacopoeia 2011) and European Pharmacopoeia (EDQM 2011) which 
recommend HPLC method for its assay. In the literature, several HPLC methods 
(Lakshmi, Rajesh and Shrinivas 2010; Shalini et al. 2010; Kanthi et al. 2008; Li, Tian 
and Kaic 2008; Varanasi et al. 2008; Danai et al. 2007; Jolly et al. 2007; Pathare, Jadhav and 
Shingare 2006–2007; Srinivas et al. 2007; Wang and Sun 2007; Zhu, Lin and Li 2006; Mao, 
Liang and Qin 2006; He, Yan and Xiaoyan 2005; Gu 2004; Steffen et al. 2003; Yang, Wang 
and Liuxi 2002) are available for the determination of NTG in human plasma, rat plasma, 
rabbit plasma, chiral and related substances. Reported methods for the determination of 
NTG in pharmaceuticals include HPTLC (Asha et al. 2011; Kale and Kakde 2011), 
spectrophotometry (Cijo et al. 2011; Sekaran, Lavudu and Prameela 2010; Jain, Bhandari 
and Purohit 2009; Suresh, Anil and Suresh 2009; Rajasekaran et al. 2004; Sagar, Rao and 
Sastry 2004; Vidya 2004; Tianbao, Li and Shengli 2003), electrokinetic chromatography 
(Hongyuan et al. 2004) and capillary electrophoresis (Zhao and Chen 2003). 
According to literature survey, there are quite a few publications on UPLC 
method development (Elie et al. 2007; Stephan and Pierre 2006) strategy but the method 
development approaches for RP-UPLC specifically focused on pharmaceutical 
development in a QbD environment for NTG have not been reported anywhere. 
Furthermore, no UPLC methods are reported for the determination of NTG in bulk and 
formulated forms. Therefore, there is an unmet need to investigate a systematic UPLC 
method development approach for pharmaceutical development using QbD principles to 
ensure the quality of the method throughout the product lifecycle.  
The primary objective of this study was to implement QbD approach to develop 
and validate an RP-UPLC method that could separate drug in the bulk and formulated 
forms from its potential related substances and to establish an in-depth understanding of 
the method and build in the quality during the method development to ensure optimum 





Materials and Reagents 
 
Pure active ingredient sample of NTG was kindly supplied by Glenmark Pharmaceuticals 
(Mumbai) as gift. Two NTG containing tablets, Natilide-60 (60 mg) [Alembic Ltd., 
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Vadodara, India] and Glinate-60 (60 mg) [Glenmark Pharmaceuticals, Mumbai] were 
procured from the local market. HPLC grade acetonitrile was purchased from Merck 
(Mumbai), potassium dihydrogenorthophosphate and orthophosphoric acid were from 
Qualigens (India). Double distilled water was used throughout the investigation. 
 
Chromatographic Conditions and Equipments 
 
Analyses were carried out on a Waters Aquity UPLC with Tunable UV (TUV) [Waters 
Corporation, Milford, MA, USA] detector. The output signal was monitored and 
processed using the built-in Empower software. The chromatographic column used was 
Acquity UPLC BEH C-18 (100 × 2.1) mm with 1.7 µm particle size. Isocratic elution process 
was adopted throughout the analysis. Mobile phase used was 40:60 (buffer:acetonitrile) 




The isocratic flow rate of mobile phase was maintained at 0.40 mL min–1. The column 
temperature was adjusted to 35°C. The injection volume was 2 µL. Eluted sample was 
monitored at 210 nm and the run time was 6.0 min. The retention time of the sample was 




Twenty mg of pure NTG was transferred into 3 different 100 mL volumetric flasks and 
added with 5 mL of 5 M HCl, 5 M NaOH or 5% H2O2 separately, and the flasks were 
heated for 2 h on a water bath maintained at 80C. Then the solutions were cooled and 
neutralised by adding base or acid, the volume in each flask was brought to the mark with 
mobile phase, and the appropriate volume (2 µL) was injected for analysis. Solid state 
thermal degradation was carried out by exposing pure drug to dry heat at 105C for 3 h. 
For photolytic degradation studies, pure drug in solid state was exposed to 1.2 million lux 
hours in a photo stability chamber (ICH 1994). The sample after exposure to heat and light 
was used to prepare 200 µg mL–1 solutions in mobile phase and the chromatographic 
procedure was followed. 
 
Preparation of Stock Solution 
 





Procedure for Preparation of Calibration Curve 
 
Working solutions containing 0.06–250 µg mL–1 of NTG were prepared by serial dilutions 
of aliquots of the stock solution. Aliquots of 2 µL were injected (six injections) and eluted 
with the mobile phase under the reported chromatographic conditions. The average peak 
area versus the concentration of NTG in µg mL–1 was plotted. Alternatively, the 
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corresponding regression equation was derived using mean peak area-concentration data 
and the concentration of the unknown was computed from the regression equation. 
 
Preparation of Tablet Extracts and Assay Procedure 
 
Twenty Natilide-60 tablets (each tablet contained 60.0 mg NTG) were weighed and 
transferred in to a clean, dry mortar and powdered. Tablet powder equivalent to 20 mg of 
NTG was transferred in to a 100 mL volumetric flask and 60 mL of the mobile phase was 
added. The solution was sonicated for 20 min to achieve complete dissolution of NTG, 
made up to the mark with mobile phase and then filtered through a 0.22 µm nylon 
membrane filter. The solution (200 µg mL-1 of NTG) obtained was analysed by UPLC. The 
same procedure was repeated with 20 Glinate-60 (each tablet contained 60.0 mg NTG) 
tablets. 
 
Procedure for Method Validation 
 
Accuracy and precision 
 
To determine the accuracy and intra-day precision, pure NTG solutions at three different 
concentrations were analysed in seven replicates during the same day. Mobile phase was 
injected as blank solution before sample injection and the relative standard deviation  
[RSD] (%) values of peak area and retention time were calculated. 
 
Limits of detection (LOD) and quantification (LOQ) 
 
The LOD and LOQ were obtained by signal to noise (S/N) ratio method and by a series of 
dilutions of the NTG stock solution. Precision study was performed at LOQ level also. 
LOQ solution was injected seven times (n=7) and the RSD % values for the obtained peak 




Linearity solutions were prepared from LOQ level to 125% of the actual sample 
concentration (200 µg mL–1 NTG). A total of six concentrations of the solutions were made 
separately and injected (LOQ 50, 100, 150, 200 and 250 µg mL–1 levels).   
 
Robustness and Ruggedness 
 
To determine the robustness of the method the experimental conditions were deliberately 
changed. The flow rate of the mobile phase (0.4±0.04 mL min–1), column oven temperature 
(35±1°C), mobile phase composition (45:55, 55:45, acetonitrile:buffer, v/v) and detection 
wavelength (210±1 nm) were the varied parameters. In each case the RSD % values were 
calculated for the obtained peak area and retention time. The number of theoretical plates 
and tailing factors were compared with those obtained under the optimised conditions. 
Three different columns of same dimensions were used for the analyses. The study was 
performed on three different days by three different analysts. The area obtained from each 
concentration was compared with that of the optimised one. The relative standard 
deviation values were evaluated for each concentration. 
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Solution Stability and Mobile Phase Stability 
 
Stability of NTG solution was investigated by injecting the sample into the 
chromatographic system. The peak area was recorded in the time intervals of 0, 12 and 24 
h and the RSD values were calculated. The mobile phase stability was studied by injecting 
a freshly prepared sample solution at the same time intervals (0, 12 and 24 h) with the 
same mobile phase and RSD values of the peak areas were calculated. 
 
 
RESULTS   
 
Method Development for Acquity BEH C8 Column, 100  2.1 mm, 1.7 µm  
 
All the trials are shown in Table 1 and chromatograms are shown in Figure 3.  
 
Method Development for Acquity BEH C18 Column, 100  2.1 mm, 1.7 µm  
 
All the trials are shown in Table 2 and chromatograms are shown in Figure 4. 
 
Method Development for C18 Using Different pH Conditions 
 
All the trials are shown in Table 3 and chromatograms are shown in Figure 5. 
 
Final Method Conditions 
 
Column  : Acquity BEH C18, 100 × 2.1 mm, 1.7 µm  
Oven temp. : 35ºC 
Mobile phase : ACN:buffer (pH 2.8; 40:60%, v/v)  
Run time : 6 min 
Flow  : 0.2 mL/min      
Diluent  : Mobile phase                 
Inj. volume : 2 µL       
Blank  : Diluent 
Wavelength : 210 nm 
 
Table 1: Observation and remarks of method development for Acquity BEH C8, 100  2.1 
mm, 1.7 µm column. 
 
S. no Trails taken  Observations Remarks 
1 
ACN:buffer (pH 2.8; 
40:60%, v/v) 
Asymmetrical peak with 
fronting and tailing 
Not satisfactory 




Completely split peak Not satisfactory 
4 
Methanol:buffer (pH 2.8; 
40:60%, v/v) 
Asymmetrical peak with tailing Not satisfactory 
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Fig. 3(c): Chromatogram for mobile phase [methanol:water (40:60%, v/v)]. 
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Fig. 3(d): Chromatogram for mobile phase [methanol:buffer (pH 2.8; 40:60%, v/v)]. 
 
 
Table 2: Observation and remarks of method development for Acquity BEH C18, 100 × 2.1 
mm, 1.7 µm column. 
 
S. no Trails taken  Observations Remarks 
1 
ACN:buffer (pH 2.8; 40:60%, 
v/v) 
Symmetrical peak Satisfactory 




Completely split peak Not satisfactory 
4 
Methanol:buffer (pH 2.8; 
40:60%, v/v) 




Fig. 4(a): Chromatogram for mobile phase [ACN:buffer (pH 2.8; 40:60%, v/v)]. 
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Table 3: Observation and remarks of method development for different pH conditions. 
 
S. no Trails taken  Observations Remarks 
1 
ACN:buffer (pH 2.8; 
40:60%, v/v) 
Peaks found symmetrical Satisfactory 
2 
ACN:buffer (pH 4; 
40:60%, v/v) 




ACN:buffer (pH 5; 
40:60%, v/v) 
Completely split peak Not satisfactory 
4 
ACN:buffer (pH 6; 
40:60%, v/v) 









Fig. 5(b): Chromatogram for mobile phase [ACN:buffer (pH 4; 40:60%, v/v)]. 
 
33   RP-UPLC Analysis of Nateglinide 
                                                          
Malay J Pharm Sci, Vol. 10, No. 1 (2012): 23–44 
 
 




Fig. 5(d): Chromatogram for mobile phase [ACN:buffer (pH 6; 40:60%, v/v)]. 
 
 
Validation of the Method 
 
The described method for the assay of NTG has been validated as per the current ICH Q2 
(R1) Guidelines. 
 
 Analytical Parameters 
 
A calibration curve was obtained for NTG from LOQ to 125% of its stock solution. A linear 
correlation was obtained between the mean peak area and the concentration in the range 
of 0.06–250 µg mL–1 NTG from which the linear regression equation was computed and 
found to be: 
 
Y = mC + a, (r = 0.9999) 
 
where Y is the mean peak area, C is the concentration of NTG in µg mL–1, a is the intercept 
and r is the correlation coefficient. The LOD and LOQ values, slope (m), y-intercept (a) 
and their standard deviations are evaluated and presented in Table 4. These results 
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confirm the linear relation between the mean peak area and concentration as well as the 
sensitivity of the method. 
 
Table 4: Linearity and regression parameters with precision data. 
 
Parameter Value 
Linear range, µg mL–1 0.1–250 
Limits of quantification, (LOQ), µg mL–1 0.06 
Limits of detection, (LOD), µg mL–1 0.02 
Regression equation  
Slope (b) 19930.392 
Intercept (a) 1015594.2 
Correlation coefficient (r) 0.9999 
Standard deviation of b, (Sb) 116.197 
Standard deviation of a, (Sa) 19269.127 
 
Accuracy and Precision 
 
The percent relative error which is an index of accuracy is ≤15 and is indicative of high 
accuracy. The calculated RSD % can be considered to be satisfactory. The peak area based 
and retention time based RSD values were <1. The results obtained for the evaluation of 
precision and accuracy of the method is compiled in Tables 5 and 6.  
 
Robustness and Ruggedness 
 
The robustness of an analytical procedure is a measure of its capacity to remain unaffected 
by small, but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage. At the deliberate varied chromatographic conditions 
(flow rate, temperature and mobile phase composition), the analyte peak RSD %, tailing 
factor and theoretical plates remained near to the actual values. The RSD values ranged 
from 0.1% to 1.7% resumes the robustness of the proposed method. In method 
ruggedness, different columns (same lot), days and analysts (n=3) were performed. The 
results are summarised in Table 7. 
 
Stability of the Solution 
 
At the specified time interval, RSD % for the peak area obtained from drug solution 
stability and mobile phase stability were within 1%. This shows no significant change in 
the elution of the peak and its system suitability criteria RSD %, tailing factor, theoretical 
plates. The results also confirmed that the standard solution of drug and mobile phase 
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Table 5: Results of accuracy study (n=5).  
 
Concentration of 








of NTG found,            
(µg mL–1) 
RE (%) 
150 147.71 1.53 147.48 1.68 
200 203.48 1.74 202.20 1.10 
250 247.15 1.14 252.10 0.84 
 
Notes: RE-relative error 
            n-number of determinations 
  





Intra-day precision (n=7) Inter-day precision (n=5) 
Mean area±SD RSDa RSDb Mean area±SD RSDa RSDb 
150 3989188±27655 0.69 0.58 3985452±27818 0.61 0.14 
200 5026677±14476 0.29 0.12 501009±14421 0.24 0.15 
250 5986874±15199 0.25 0.13 5976126±16232 0.26 0.19 
 
Notes: aRSD based on peak area 
            bRSD based on retention time 




Selectivity of the method was evaluated by injecting the mobile phase, placebo blank, pure 
drug solution and tablet extract. No peaks were observed for mobile phase and placebo 
blank and no extra peaks were observed for tablet extracts [Figs. 6(a) and 6(b)]. 
 
Application to Tablet Analysis 
 
A 200 µg mL–1 solution of tablets was prepared and injected in triplicate to the UPLC 
system. From the mean peak area, the concentration and hence mg/tablet were computed; 
and the results were compared with those of a reference method (United States 
Pharmacopoeia 2011). The reference method involved the HPLC analysis with sodium 
phosphate buffer in methanol with a pH of 7.5, wavelength was set at 210 nm and 6 mm, 
15 cm; 6 µm packing L71 column was used. The accuracy and precision of the proposed 
method were further evaluated by applying Student’s t-test (<2.7) and variance ratio F-test 
(<6.4), respectively. The t- and F- values at 95% confidence level did not exceed the 
tabulated values and this further confirms that there is no significant difference between 
the reference and proposed methods with respect to accuracy and precision. Table 8 
illustrates the results obtained from this study. 
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Fig. 6(b): Chromatogram for tablet extract.  
 
 
Table 8: Results of determination of NTG in formulations and statistical comparison with 







% NTG foundc ± SD 

















Notes:  a Marketed by Alembic Ltd. (Vadodara, India)  
                   bMarketed by Glenmark Pharmaceuticals (Mumbai) 
 cMean value of 5 determinations. Tabulated t-value at 95% confidence level is 2.78; 
tabulated F-value at 95% confidence level is 6.39 
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Stress Study 
 
No degradation products were formed during the stress studies with 5 M HCl, 5 M 
NaOH, 5% H2O2, hydrolytic, thermal and photolytic conditions. Figure 7 shows the 












Fig. 7(c): 5 M NaOH degradation. 
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Recovery Study  
 
A standard addition procedure was followed to evaluate the accuracy of the method. The 
solutions were prepared by spiking pre-analysed tablet powder with pure NTG at three 
different levels and injected to chromatographic column after sample preparation as 
described before. The recovery of the known amount of added analyte was computed. The 
percentage recovery of NTG from pharmaceutical dosage forms ranged from 97.57% to 
101.1%. Detailed results presented in Table 9 reveal good accuracy of the proposed 
method. 
 
Table 9: Results of recovery study by standard addition method. 
 
Tablet studied 
NTG tablet           
(µg mL–1) 
NTG pure              
(µg mL–1) 
Total NTG 
found         
(µg mL–1) 
Percent recovery of 
pure NTG 
(% NTG±SD) 
Natelide 60 98.88 50 145.26 97.57±0.84 
98.88 100 194.54 97.82±0.47 
98.88 150 249.63 100.3±0.73 
Glinate 60 99.94 50 149.12 99.45± 0.80 
99.94 100 193.26 96.66±0.56 





UPLC becomes very prominent in recent years due to its fast approach towards drug 
method development and validation. The smaller particles in column provide not only 
increased efficiency, but also the ability to work at increased linear velocity without a loss 
of efficiency, providing both resolution and speed. This method discusses in detail the 
QbD approach towards development and validation of NTG with vital information about 
its degradation in different stress conditions. The study reveals that the drug is sensitive 
towards pH and buffer mobile phases. Though the drug is soluble in solvents like 
methanol which is less costly, acetonitrile was found suitable for this method. QbD 
development reveals that the Acquity BEH C18, 100 × 2.1 mm, 1.7 µm column is the 
appropriate one for this method compared to columns. According to the van Deemter 
equation (Garry 2007), as the particle size decreases to less than 2.5 µm, the efficiency 
gains significantly (Michael 2005). The small particles in the column play a vital role in 
gaining the higher efficiency. The robustness and ruggedness study provides sufficient 
information on the repeatability and reproducibility of the method. The quantitation and 
detection limits are 0.06 µg mL–1 and 0.02 µg mL–1 respectively and the linearity ranges 
from 0.06–250 µg mL–1. NTG was found to be very stable towards acidic, basic, oxidative, 
thermal and photolytic stress conditions. 
A reversed phase UPLC method development approach using QbD principles 
has been described. First, the method goals are clarified based on the process 
understanding. The experimental design describes the scouting of the key UPLC method 
components including column, pH and mobile phase. The interrelationships are studied 
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and the preliminary optimised conditions are obtained for each combination. Here a better 
understanding of the factors influencing chromatographic separation and greater 
confidence in the ability of the methods to meet their intended purposes is done. 
Moreover, this approach provides a thorough knowledge and enables the creation of a 
chromatographic database that can be utilised to provide alternative method conditions at 
a future time, whenever the changes to the method are required for the assay of both 
forms of the drug. The new method boosts productivity by providing more information 
per unit of work as UPLC provides higher resolution, speed, and sensitivity predicted for 






The validated method is specific, linear, precise, accurate, robust, rugged and stable for        
24 h and can be applied for the determination of NTG in formulated form. The drug is 
stable in acidic, basic, oxidative, thermal, photolytic and hydrolytic conditions. The 
potential of QbD approach for simultaneous development of multiple methods including 
impurity methods, assay method, dissolution method, and cleaning validation method, 
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